CV Sciences
San Diego, United States · Fitness, Health Care, Other
The Company expects to use net proceeds of approximately $1 million, before deducting transaction fees and other estimated transaction expenses, from this offering for general corporate purposes which may include, without limitation, funding of product development, sales and marketing activities, increasing the Company’s working capital and investment in its products and intellectual property in o
Funding history
- Convertible Note — Undisclosed — Nov 2021
- Seed — $750K — Apr 2017
- Seed — $2.0M — Jun 2016
Recent signals
- Mar 26, 2026: SEC 8-K (7.01): On March 26, 2026, CV Sciences, Inc. issued a press release disclosing its financial results for the fiscal year and quarter ended December 31, 2025. The press release contains non-GAAP financial measures as defined in Regulation G, along with reconciliations to the most directly comparable GAAP financial measures. This disclosure is significant as it provides insights into the Company’s financial performance and strategic positioning going forward. The timing of this disclosure is critical as it directly relates to the Company's recent financial results, aimed at informing shareholders and the market of its operational success and future prospects.
- Mar 12, 2026: Launched CV Sciences has launched Empowr, a plant-based protein and creatine formula for total wellness.
- May 13, 2024: CV Sciences, Inc. completes acquisition of Elevated Softgels, LLC to enhance product flexibility
- Dec 12, 2023: Cv Sciences, Inc. Acquires Cultured Foods To Enter Plant-Based Food Market, Opening Door For European Distribution
- Nov 15, 2021: Raised funding in Convertible Note
- Apr 03, 2017: Raised $750K in Seed
- Jun 08, 2016: Raised $2.0M in Seed
See plans & pricing → Track CV Sciences’s funding, hiring, and signals — with verified contacts — on Fundz.